BEGIN:VCALENDAR
VERSION:2.0
PRODID:-//AssetMemo//Readout calendar//EN
CALSCALE:GREGORIAN
METHOD:PUBLISH
X-WR-CALNAME:SAL0137 readouts · AssetMemo
X-WR-CALDESC:Upcoming readouts of SAL0137\, from ClinicalTrials.gov estimat
 es.
REFRESH-INTERVAL;VALUE=DURATION:PT12H
X-PUBLISHED-TTL:PT12H
BEGIN:VEVENT
UID:NCT07729475-1077@assetmemo.bio
DTSTAMP:20261121T005559Z
DTSTART;VALUE=DATE:20261212
DTEND;VALUE=DATE:20261213
SUMMARY:SAL0137: Phase 2 readout est. (NCT07729475)
DESCRIPTION:SAL0137\, phase 2\, Atherosclerotic Cardiovascular Disease.\nSt
 udy: A Phase II\, Randomized\, Double-Blind\, Placebo-Controlled Study of 
 Oral SAL0137 in Adults With Elevated Lp(a) and Increased Risk of Cardiovas
 cular Events\nEstimated primary completion: 12 December 2026. This is a Cl
 inicalTrials.gov estimate\, not a confirmed readout date\, and it can move
 .\nDrug page: https://assetmemo.bio/drug/sal0137#upcoming-events\nRegistry
  record: https://clinicaltrials.gov/study/NCT07729475
URL:https://assetmemo.bio/drug/sal0137#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
END:VCALENDAR
